














This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Altmann T, Gennery AR.  
DNA ligase IV syndrome; a review.  




This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and 
reproduction in any medium, provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative 
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) 
applies to the data made available in this article, unless otherwise stated. 
DOI link to article: 
http://dx.doi.org/10.1186/s13023-016-0520-1  
Date deposited:   
07/12/2016 
REVIEW Open Access
DNA ligase IV syndrome; a review
Thomas Altmann1 and Andrew R. Gennery1,2*
Abstract
DNA ligase IV deficiency is a rare primary immunodeficiency, LIG4 syndrome, often associated with other systemic
features. DNA ligase IV is part of the non-homologous end joining mechanism, required to repair DNA double
stranded breaks. Ubiquitously expressed, it is required to prevent mutagenesis and apoptosis, which can result from
DNA double strand breakage caused by intracellular events such as DNA replication and meiosis or extracellular
events including damage by reactive oxygen species and ionising radiation.
Within developing lymphocytes, DNA ligase IV is required to repair programmed DNA double stranded breaks
induced during lymphocyte receptor development.
Patients with hypomorphic mutations in LIG4 present with a range of phenotypes, from normal to severe
combined immunodeficiency. All, however, manifest sensitivity to ionising radiation. Commonly associated features
include primordial growth failure with severe microcephaly and a spectrum of learning difficulties, marrow
hypoplasia and a predisposition to lymphoid malignancy. Diagnostic investigations include immunophenotyping,
and testing for radiosensitivity. Some patients present with microcephaly as a predominant feature, but seemingly
normal immunity. Treatment is mainly supportive, although haematopoietic stem cell transplantation has been
used in a few cases.
Keywords: DNA Ligase 4, Severe combined immunodeficiency, Primordial dwarfism, Radiosensitive, Lymphoid
malignancy
Background
DNA ligase IV deficiency (OMIM 606593) or LIG4 syn-
drome (ORPHA99812), also known as Ligase 4 syn-
drome, is a rare autosomal recessive disorder
characterised by microcephaly, abnormal facial features,
sensitivity to ionizing radiation and combined immuno-
deficiency. Additional features can include developmen-
tal delay, bony deformations, skin conditions and
susceptibility to malignancy (Table 1). It is caused by
mutations in LIG4 that encodes a key component of the
ubiquitous non-homologous end-joining (NHEJ) path-
way essential for the DNA double strand break (DSB) re-
pair mechanism that is also utilized in the production of
T and B lymphocyte receptors.
DNA damage and repair
DNA is constantly damaged in ways that, if left unre-
paired, may lead to genetic sequence errors. Damaging
factors include intracellular events such as DNA replica-
tion and meiosis, and extracellular events including
damage by reactive oxygen species and ionising radi-
ation. In order to maintain genomic integrity and stabil-
ity, pathways have evolved to recognise and correct
these errors. In mammalian cells the pathways include
NHEJ, homologous recombination, base excision repair
and DNA mismatch repair. Defects in any of the compo-
nents of these pathways may allow DNA replication er-
rors, such as addition, loss or rearrangement of genetic
information. Errors of DNA-DSB repair are particularly
damaging and may lead to mutagenesis causing carcino-
genesis or premature cell death by apoptosis [1, 2]. Two
DNA repair pathways have evolved to deal with these le-
sions. Homologous recombination utilises information
from a homologous template to accurately repair breaks,
when sister chromatids present readily available tem-
plates, generally limited to late S phase and G2 phase of
the cell cycle in mammalian cells. When extensive hom-
ology is lacking NHEJ is the main DNA-repair pathway
that mediates the joining of broken regions of DNA, and
is the principle mechanism used in vertebrate cells
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during the G1 phase of the cell cycle. Individuals who
harbour genetic mutations in components of DNA-DSB
repair, demonstrate cellular sensitivity to ionising radiation
and chemicals which induce DNA-DSB, and are more sus-
ceptible to developing oncogenic lesions.
As well as protecting genomic integrity, DNA-DSB re-
pair pathways are utilised in adaptive immunity in the
production of T- and B-lymphocytes. In order to counter
any potential invading pathogen, a broad spectrum of T-
and B-lymphocyte receptors must be produced to ensure
they are able to recognise all possible threats [3]. This is
ensured by variable, diverse and joining (V(D)J) recom-
bination, a system of targeted DNA damage, in the form
of programmed DNA-DSB and repair that has evolved
to achieve this stochastically diverse T- and B-
lymphocyte repertoire [2].
DSB repair: NHEJ
The most rapid mechanism for the repair of DNA-DSB in
mammalian cells is the NHEJ pathway. The classical NHEJ
pathway, of which DNA Ligase IV is a critical component,
is active in all stages of the cell cycle, but most active in
G0 and G1 phases [4]. An alternative NHEJ pathway, most
active in the S and G2 phases of the cell cycle, is
dependent on signalling by poly(ADP-ribose) polymerase
1, utilizes microhomolgy, and is used when elements of
the classical pathway are dysfunctional. Un-repaired
DNA-DSB have a high probability of leading to mutagen-
esis and oncogenesis or apoptosis [4]. It is estimated that
the average mammalian cell incurs 10 to 50 DNA-DSB
per day, mostly by reactive oxygen species.
The presence of a DNA-DSB, generated through non-
programmed events or programmed V(D)J recombination
is recognised by a complex of which the constituent parts
are MRE11, RAD50 and Nijmegen breakage syndrome
protein 1 (Nibrin previously called NBS1) [4]. Ku70/80
subsequently binds the break and the DNA-Ku70/80 com-
plex recruits the DNA dependant protein kinase catalytic
subunit (DNA-PKcs) and activates the kinase activity.
During this process, the DNA-Ku70/80-DNA-PKcs com-
plex recruits proteins including Artemis, DNA ligase IV,
XRCC4 and Cernunos-XLF to ligate the breakage site.
Once the components are in place, DNA-PKcs is autop-
hosphorylated and in turn phosphorylates Artemis. This
enables Artemis/DNAPKcs to function as an endonucle-
ase, leading to cleavage of 5’ and 3’ DNA overhangs. The
DNA ligase IV/XRCC4/Cernunos-XLF complex AMP
moiety temporarily attaches to the ends of the DNA and
ensures ligation of the DNA-DSB [1, 2]. DNA-DSB often
have complex ends so that the structure of aligned ends
may prevent juxtaposition of strand break termini because
ends have damaged or adducted nucleotides, mis-pairs,
nucleotide gaps or hairpins. Polymerase μ fills gaps cre-
ated by the breakage process to generate ends that can
be efficiently ligated but adding complementary nucleo-
tides after bridging noncomplementary ends [5, 6].
During V(D)J recombination terminal deoxynucleotidyl
transferase (TdT), a polymerase structurally related to
polμ adds nucleotides in a template-independent reac-
tion, to increase junctional diversity at the V(D)J join,
and thus increase the diversity of the lymphocyte recep-
tor repertoire [7].
Somatic recombination
The adaptive immune system is able to mount an effect-
ive immune response against a wide range of foreign
pathogens, achieved by generation of an estimated 108
cells each with their own unique antigen receptor that is
able to recognise a single antigen-major histocompatibil-
ity complex (MHC) [8]. The process of stochastic re-
arrangement and re-joining of DNA sequences that code
for the antigen recognition region of the receptors en-
ables this diverse number of unique adaptive immune
cells to be produced. This is known as V(D)J recombin-
ation and it is achieved by adapting pre-existing DNA
damage repair mechanisms to repair the programmed
DNA-DSB created during the recombination process.
V(D)J recombination occurs in early T-lymphocyte
thymic development, affecting α, β, γ and δ loci of the T
Cell Receptor (TCR), and maturing B-lymphocytes in
the bone marrow, affecting B Cell Receptor (BCR)/im-
munoglobulin heavy chain loci and immunoglobulin k
and λ light chain loci.
Events during V(D)J recombination
During G1 in the cell cycle, the RAG1/RAG2 complex
induces site specific DNA-DSB at conserved non-coding
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DNA recombination signal sequence (RSS) on both sides
of the site randomly targeted for recombination, forming
two DNA ends:
1. Coding sequence ends formed as hairpin
intermediates that reform immunoglobulin and TCR
genes.
2. Blunt double stranded DNA non-coding signal ends
that contain motifs for targeting site-specific DNA
cleavage between the two RSS sites.
During this process ataxia-telangiectasia mutated
(ATM) protein assists in stabilisation of the exposed
DNA ends within the RAG complex. Nibrin, γH2Ax and
53BPI also migrate to the DNA-DSB and chromatin re-
gion of the recombining loci to stabilise the process [2].
Once the recombination has occurred the DNA-DSB are
repaired by the NHEJ mechanism, described above.
If any of the NHEJ components are dysfunctional
V(D)J recombination is not entirely lost. An alternative
pathway exists utilising microhomology as a means to
repair DSBs. However this pathway leads to a multitude
of nucleotide deletions [9]. Theoretically the limited
DNA repair that occurs in this alternative pathway could
lead to production of a reduced number of unique anti-
gen recognising receptors.
LIG4 structure and models of LIG4
Lig4 is located on chromosome 13q33–q34 [10].
Complete knockout of LIG4 in mice is embryological le-
thal and mutations described in humans are hypo-
morphic, leading to significantly impaired NHEJ but still
maintaining some activity. Various murine models have
confirmed the hypomorphic nature of LIG4 mutations
seen in humans. One lacked a single copy of LIG4, and
due to impaired NHEJ, cells showed excessive sensitivity
to ionising radiation [11]. Human fibroblast cell lines de-
veloped from LIG4 patients also show significant radio-
sensitivity [12–18]. Nijnik and Rucci produced murine
models of LIG4 syndrome that show great similarities
with that of humans. Mice were immunodeficient;
growth restricted and demonstrated progressive bone
marrow failure as they aged [19, 20]. The cause of pro-
gressive bone marrow failure in LIG4 mouse models and
humans is due to a progressive accumulation of DNA-
DSB in haematopoietic pluripotent stem cells leading to
cellular apoptosis [21].
Epidemiology
Little is known of the prevalence of LIG4 syndrome.
Globally only 28 cases have been described [12–18,
22–27] and additionally a small number of unpub-
lished cases have been treated by haematopoietic stem
cell transplant (HSCT) (personal communication, AR.
Gennery). No formal estimate of prevalence has been
made to date.
Clinical presentation and complications
The first patient described with a LIG4 mutation was de-
velopmentally and clinically normal with no microceph-
aly, but developed acute lymphoblastic leukaemia and
following chemotherapy treatment developed profound
leukopenia. Standard consolidation chemotherapy was
omitted but prophylactic cranial radiotherapy proved
devastating. He developed marrow hypoplasia, a des-
quamating rash over his scalp and bilateral mastoid radi-
ation ulcers and died 8 months later from radiation-
induced encephalopathy [25]. A fibroblast cell line,
180BR, was found to have defective DNA DSB repair.
The authors investigated the NHEJ pathway in 180BR
cells finding normal levels of DNA-PK, XRCC4 and
DNA LIG4. Mutated DNA LIG4 in 180BR was unable to
form stable enzyme-adenylate complexes. At high levels of
ATP some complex forming activity was measured in
180BR, which may explain why the patient did not have
any signs of overt immunodeficiency and had intact V(D)J
recombination. However the defect was severe enough
that 180BR was unable to repair radiation-induced DNA
DSB for which maximum DNA Ligase IV activity may be
required [15]. Since this first case was described, 27 fur-
ther cases have been published with a broad spectrum of
clinical features [12–18, 22–27].
Physical features
The most common, although not universal, finding is
that of congenital non-progressive microcephaly, de-
scribed in 26 of the 28 patients. Sporadic physical devel-
opmental issues are described, the most common of
which is severe growth restriction, which co-exists with
microcephaly, and begins in-utero. Abnormal facial fea-
tures are common with four patients described as “bird-
like” or “Seckel syndrome-like” (beak-like nose, promin-
ent mid-face, receding forehead and micrognathia) facial
features and 13 with bilateral epicanthic folds and
nose changes [24, 27]. Eight patients have been de-
scribed with bone abnormalities including bone hypo-
plasia, syndactyly, polydactyly and congenital hip
dysplasia. Three patients have been described with
hypogonadism presenting with primary amenorrhea or
failing to progress through puberty [23, 24, 27]. Ten
patients presented with a variety of skin disorders in-
cluding photosensitivity, psoriasis, eczema, erythro-
derma, widespread ecchymosis and hypopigmentation
[16, 22–24, 27].
Developmental features
A wide spectrum of neurodevelopmental delay is evident
in LIG4 deficiency ranging from individuals who appear
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to have no developmental delay to those that suffer from
profound learning difficulties [23, 28]. Microcephaly and
neurodevelopmental delay are frequently present and
characteristic. Microcephaly, which is evident prenatally,
may result from emission of reactive oxygen species by
rapidly replicating neurones in foetal development.
These induce oxidative damage causing an accumulation
of DNA-DSB, which causes irreversible collapse of DNA
replication forks, halting neuronal cell development [29].
Immunodeficiency
Due to disruption in V(D)J recombination, LIG4 syn-
drome is associated with immunodeficiency. Twelve pa-
tients have been reported with LIG4 syndrome after the
finding of combined immunodeficiency (CID) with pro-
found T- and B-lymphocytopenia and varying degrees of
hypogammaglobulinaemia, often associated with a raised
IgM due to defective isotype class switching, which also
relies on programmed DNA-DSB. There is increased
susceptibility to bacterial, viral and fungal infection lead-
ing to multiple hospital admissions and failure to thrive.
The most severe form of immunodeficiency, severe com-
bined immunodeficiency (SCID), has been described in
four patients [12, 14, 18, 23]. Additionally, one patient
has been described with SCID and features of Omenn’s
syndrome [22], more frequently associated with hypo-
morphic RAG1/2 defects leading to abrogated V(D)J re-
combination [30]. Autoimmunity was described in one
patient [9].
Malignancy
Defective DNA-DSB repair represents a substantial risk
factor for mutagenesis and the development of malig-
nancy. Six LIG4 patients have been reported in the lit-
erature, presenting with malignancy. Lymphoma affected
three patients including two with Epstein-Barr virus as-
sociated lymphoma [13, 26, 31, 32]. One patient with
Dubowitz syndrome developed malignant squamous cell
carcinoma and was diagnosed with a LIG4 mutation
retrospectively [16].
Phenotype-genotype correlations
LIG4 syndrome has a broad clinical presentation and
phenotype. Most cases described to date have missense
LIG4 mutations or nucleotide deletions displaying a
range of phenotypic presentations [12–15, 24, 26, 27].
The missense mutations lead to 5-10 % of LIG4 func-
tion: these patients present with CID [12, 13, 22, 26].
Truncating (nonsense) mutations, depending on location
within the gene, present with a range of signs (Fig. 1).
Some present with no evidence of immunodeficiency
and others with SCID. Murray et al. [23] found that a
genotype–phenotype correlation was seen with the pos-
ition of truncating mutations corresponding to disease
severity. The authors found that the “early” truncating
mutations, which caused the addition of an early stop
codon that produced the shortest of the proteins, re-
sulted in the most severe phenotypes with these patients
developing SCID [23].
Diagnosis
Diagnosis of LIG4 is initiated by clinical suspicion. Clin-
ical findings of the main characteristics, namely micro-
cephaly, combined immunodeficiency with or without
developmental delay, are sufficient to confirm a rare im-
munodeficiency possibly involving defective DNA repair
pathways. Clinical laboratory features that increase sus-
picion include marrow hypoplasia with anaemia and
thrombocytopenia, lymphocytopenia with marked B-
lymphocytopenia, panhypogammaglobulinaemia or evi-
dence of isotype class-switching impairment with raised
IgM and absent or low IgA and IgG.
In T- and B-lymphocytes from patients, there is bio-
chemical evidence of reduced class switch recombin-
ation with increased use of microhomology-mediated
end-joining at switch junctions and in TRB and IGH
junctions and use of long microhomology. Additionally,
Fig. 1 The structure of DNA LIG4 with the localisation of mutations found in patients with DNA LIG4 Syndrome. Blue colour denotes mutations
that are associated with CID. Red denotes mutations that are associated with SCID. Boxes around mutations denote mutations that are associated
with developing malignancies
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there is a lack of Sμ-α junctional mutations [32, 33]]. In
the T- and B-lymphocyte receptor, there may be restric-
tion of CDR3 length and diversity [30]. In experimental
cell models, a small reduction in V(D)J frequency has
been found, with a significant reduction in fidelity of sig-
nal joins [21].
In many patients, there is increased chromosome 7:14
translocation on karyotype analysis. Clonogenic survival
assays confirm radiosensitivity, performed by subjecting
fibroblasts from the patient to increasing doses of ionis-
ing radiation and measuring percentage survival of the
cells after a fixed time period [34]. Delayed DNA-dsb re-
pair kinetics can be measured by assessing appearance
and resolution of γH2AX foci in irradiated cells [35].
The frequency of V(D)J recombination [36] and fidelity
of signal joint formation [37] can be assessed using re-
combination substrates in a fibroblast cell line generated
from the patient.
Once radiosensitivity is confirmed, specific genetic
testing for LIG4 and other DNA repair genes can be per-
formed. To date, no patients with mutations in LIG4
have been described who do not exhibit sensitivity to
ionising radiation.
Modified clinical presentations
Until recently LIG4 syndrome was only identified
through genetic testing after the diagnosis of immuno-
deficiency and/or malignancy in microcephalic patients.
Murray et al. observed this and took the reverse ap-
proach to diagnosis. The authors screened 138 patients
with microcephalic primordial dwarfism for DNA Ligase
IV mutations. Eleven microcephalic primordial dwarfism
patients were identified as having LIG4 syndrome all off
whom had cellular radiosensitivity. Nine developed cyto-
penia due to bone marrow failure requiring transfusion,
seven of whom developed cytopenia post-LIG4 screen-
ing. Interestingly no patients were diagnosed with CID
before screening and only one patient was diagnosed
with SCID. Retrospectively a further six patients showed
signs of CID, most with increased infection rate, low B-
lymphocyte numbers and hypogammaglobulinaemia.
Four required HSCT due to significant immunodefi-
ciency. This may be due to the accumulation of DNA-
DSB, and therefore progressive apoptosis, in haemato-
poietic stem cells of LIG4 patients causing progressive
immunodeficiency as lymphocytogenesis reduces over
time [21]. None of the patients identified through the
authors screening had developed malignancy [23], pos-
sibly indicating that malignancy in LIG4 syndrome is a
late feature of the disease. As with an increasing number
of immunodeficiencies, mild phenotypes with a lack of
genotype/phenotype correlation may be encountered. A
family with LIG4 syndrome has recently been described
in which three mutated siblings showed cellular and
molecular features of the disease, but two were asymp-
tomatic, indicating that within families the phenotype
can vary dramatically [38].
Differential diagnosis
A number of conditions have features that overlap with
LIG4 syndrome. Nijmegen breakage syndrome (NBS)
patients harbour NBN mutations, the product of which,
nibrin, is involved in recognising DNA-DSB [4]. This
leads to similar “bird-like” facial features, microcephaly
and neurodevelopmental delay as exhibited by LIG4 pa-
tients. NBS patients are prone to respiratory infections
due to T-lymphocytopenia and variable hypogammaglo-
bulinaemia. Autoimmunity is described in a few patients.
Almost 50 % show a predisposition to lymphoid malig-
nancy [39].
A few patients with Cernunnos-XLF deficiency are de-
scribed with mutations in NHEJ1, who present with
similar physical and neurodevelopmental features, CID
with T- and B-lymphocytopenia, isotype class switching
defects and recurrent infections. Cernunnos-XLF pa-
tients, like LIG4, have also co-presented with bony mal-
formations [2]. Cernunnos-XLF is a core component of
the NHEJ complex and interacts closely with LIG4 dur-
ing the DNA-DSB ligation process.
The third enzyme that makes up the NHEJ ligation en-
zyme complex is XRCC4, which interacts strongly with
LIG4 through a tandem BRCA1 carboxyl terminal do-
main in LIG4 and a coiled-coil region in XRCC4, to
form a highly stable complex. A number of patients have
recently been reported with mutations in XRCC4.
Phenotypically, the clinical presentation is similar to pa-
tients with LIG4 syndrome, with characteristic micro-
cephaly and neurodevelopmental delay. Interestingly,
given that XRCC4 is required to stabilise LIG4, it is sur-
prising that to date, none of the patients described ex-
hibit clinical immunodeficiency, despite the marked
DNA-DSB repair defect. A molecular alteration in repair
pattern is described during class switch recombination,
but V(D)J recombination appears normal [40].
Fanconi anaemia is characterized by bone marrow fail-
ure, often accompanied by other anomalies including
skeletal, renal, cardiac and gastrointestinal defects, skin
hypo-pigmentation and predisposition to malignancy,
particularly leukemia. Most immunological manifesta-
tions relate to bone marrow failure, but some patients
present in infancy or early childhood with significant or
prolonged infections, more consistent with immunodefi-
ciency [41]. Microcephaly is not a feature of Fanconi an-
aemia. Laboratory assessments include a diepoxybutane
or mitomycin C chromosome fragility test of blood lym-
phocytes. Fifteen genes associated with Fanconi anaemia
have been identified, that have a role in repairing DNA
inter-strand crosslink damage. Cells generally show
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hypersensitivity to agents that cause DNA inter-strand
crosslinks, but a few also demonstrate sensitivity to ion-
ising radiation [42]. Fanconi anaemia proteins do not
have direct a role in lymphocyte receptor development
or modification. The immunological effects more likely
result from the effects of inter-strand DNA crosslinks
occurring during cellular development, which lead to
bone marrow failure.
ATR-Seckle Syndrome which also presents with micro-
cephaly and “bird-like” facial features occurs due to abnor-
mal function in ATR, a protein that monitors single
stranded DNA replication errors at replication forks [43].
However cases reported have a normal immunological
profile although some have developed lymphoid malig-
nancies [28, 44]. The crucial biochemical difference
between ATR-Seckle and LIG4 is that ATR-Seckle cells do
not display radiosensitivity to ionising radiation.
Treatment
Initial treatment of LIG4 syndrome is supportive, with
haematological support of marrow hypoplasia as re-
quired, longterm antibiotic, antiviral and antifungal
chemoprophylaxis and immunoglobulin substitution. Pa-
tients remain at risk of severe infections because of
chemo-prophylaxis resistance or compliance issues, and
the risk of lymphoid malignancy increases with time. Ex-
cessive exposure to ionising radiation should be avoided
where possible, and radiographic and computerised tom-
ography should be avoided where possible. Haematopoi-
etic stem cell transplantation is a curative treatment for
CID and SCID immunophenotypes, and might reduce
the long-term risk of developing lymphoid malignancy
due to improved tumour surveillance. Because of the ra-
diosensitivity displayed by LIG4, conditioning regimes
should not include irradiation. A low intensity or modi-
fied Fanconi anaemia-based conditioning regimen may
give the best possible survival, and restoration of normal
immunity and marrow hypoplasia, and alkylating agents
should be avoided [45]. Longterm effects of this ap-
proach need to be determined, and there may be a risk
of secondary tumours given the systemic nature of LIG4
deficiency. Determining optimum treatment for LIG4
deficiency should be assessed on an individual basis. Fac-
tors such as immunological profile, infection rate and se-
verity, missed school days and dependency on blood
products, amongst others, should be considered when
choosing the most appropriate treatment. It should be
noted that HSCT has no effect on microcephaly or neu-
rodevelopmental delay in these patients [22].
Information on haematopoietic stem cell transplantation
is available on ten patients [12–14, 17, 22, 24, 27, 46] and
has been successful in four cases. Four patients died (2
from multi-organ failure during the conditioning period,
one from Epstein Barr virus-driven post-transplantation
lymphoproliferative disease, and one from hepatic veno-
occlusive disease), all of whom received alkylating agents;
six patients have survived, three received reduced intensity
conditioning.
Excellent social care ensures LIG4 syndrome patients
maintain a good quality of life. Extra support is required
for parents with children with neurodevelopmental delay,
children benefit from attending schools with a positive en-
vironment for people with learning difficulties [17].
Conclusions
LIG4 syndrome is an extremely rare condition characterised
by microcephaly, abnormal “bird-like” facial features, neuro-
developmental delay and immunodeficiencies with radiosen-
sitivity. Specific features that should raise diagnostic
suspicion include prenatal microcephaly with growth retard-
ation and developmental delay, marrow hypoplasia, recurrent
infection with lymphocytopenia, and hypogammaglobulinae-
mia, often with a raised IgM. Haematopoietic stem cell trans-
plantation for immunodeficiency can be curative but it is not
without its complications, and reduced intensity conditioning
regimens should be utilised, with omission of radiotherapy.
In both human cases and mouse models, bone marrow fail-
ure and immunodeficiencies can be progressive. It may be
beneficial to screen patients with clinical characteristics of
LIG4 syndrome in order to diagnose and potentially treat im-
munodeficiency before development of significant sequalae
in order that early intervention with antimicrobial prophy-
laxis, immunoglobulin replacement and possibly HSCT can
be considered.
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